A clinical trial to observe patients with a diagnosis of COVID-19, who have previously taken part in an AT-527 COVID-19 clinical trial
A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study
- Infectious Diseases
- COVID-19 Pneumonia
- COVID-19
Terminated
- Aalborg
- Ankara
- București
- Caracal
- Ciudad de México
- Distrito Federal
- Dnipro
- Guadalajara
- Ivano-Frankivs'k
- İzmir
- Kharkiv
- Kyiv
- Köln
- København
- Mar del Plata
- Namur
- Paraná
- Pernambuco
- Roskilde
- Santiago de Querétaro
- Sibiu
- São Paulo
- thuin
- Torreón
- Trabzon
- Vinnytsia
- Zaporizhzhia
- Zürich
NCT05059080 2021-000627-12 CV43140
Trial Summary
This study will evaluate the long-term sequelae of COVID-19 in patients diagnosed with COVID-19 who previously enrolled in a RO7496998 (AT-527) study (i.e. parent study NCT04889040 [CV43043]), for approximately 6 months after the end of the parent study.
A Multicenter, Observational, 6-Month Follow-up Study of Patients With COVID-19 Previously Enrolled in a RO7496998 (AT-527) Study
Eligibility Criteria
- Participant was diagnosed with COVID-19 and enrolled in a Phase III RO7496998 (AT-527) COVID-19 study
- Participation in an interventional study at the time of enrollment or plans to enroll in an interventional study during this study.
- Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
For the latest version of this information please go to www.forpatients.roche.com